首页> 外文期刊>Journal of Crohn’s & colitis >Bacterial and Fungal Profiles as Markers of Infliximab Drug Response in Inflammatory Bowel Disease
【24h】

Bacterial and Fungal Profiles as Markers of Infliximab Drug Response in Inflammatory Bowel Disease

机译:细菌和真菌谱系作为炎症性肠病中英夫利昔单抗药物反应的标志物

获取原文
获取原文并翻译 | 示例
       

摘要

Background and Aims: Inflammatory bowel diseases [IBDs], Crohn's disease [CD] and ulcerative colitis [UC], are globally increasing chronic gastro-intestinal inflammatory disorders associated with altered gut microbiota. Infliximab [IFX], a tumour necrosis factor [TNF]-alpha blocker, is used to treat IBD patients successfully, though one-third of the patients do not respond to therapy. No reliable biomarkers are available for prediction of IFX response. Our aims were to investigate the faecal bacterial and fungal communities during IFX therapy and find predictors for IFX treatment response in IBD patients.
机译:背景和目的:炎症性肠病[IBD]、克罗恩病[CD]和溃疡性结肠炎[UC]是全球范围内与肠道微生物群改变相关的慢性胃肠炎性疾病的增加。英夫利昔单抗[IFX]是一种肿瘤坏死因子[TNF]-α受体阻滞剂,用于成功治疗IBD患者,尽管三分之一的患者对治疗没有反应。没有可靠的生物标志物可用于预测IFX反应。我们的目的是调查IFX治疗期间的粪便细菌和真菌群落,并寻找IBD患者IFX治疗反应的预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号